The Lynx Group
Cholangiocarcinoma News

2021 Cholangiocarcinoma Year in Review

2021 Year in Review: Cholangiocarcinoma — December 17, 2021
Rachna T. Shroff, MD, MS
Chief
Section of GI Medical Oncology, Director
UACC Clinical Trials Office, Director, Arizona Clinical Trials Network
Vice Chair for Clinical Research
Department of Medicine
Associate Professor of Medicine, Division of Hematology/Oncology
University of Arizona Cancer Center (UACC)
Tucson, AZ

Colleagues,

In 2021, the COVID-19 pandemic continues to impact the practice of medicine and dissemination of treatment advances presented in scientific forums. Adapting to the changes, societies such as the American Society of Clinical Oncology (ASCO), Gastrointestinal Cancers Symposium, and European Society for Medical Oncology (ESMO) have adopted virtual formats that delivered cutting-edge research in the advancement of oncology care. Recognizing the challenges of the virtual format in terms of reach and impact, we are bringing the Year in Review series that seeks to disseminate key information on treatment advances to clinicians in a timely and effective manner.

This edition of Year in Review is focused on cholangiocarcinoma (CCA), which is a diverse group of malignancies characterized by genomic heterogeneity that potentially drives its pathogenesis. Below is a quick review of some of the topics discussed in this issue, with a focus on recent advances, potentially practice-changing developments, and ongoing challenges in CCA.

Increased understanding of the CCA genetic landscape has led to identification of actionable alterations such as FGFR and IDH aberrations, for which therapeutic interventions are being developed and actively investigated. Infigratinib is a selective FGFR1-3 tyrosine kinase inhibitor that was approved in 2021 for patients with advanced, metastatic CCA bearing FGFR2 alterations. Final results of the pivotal phase 2 study demonstrated that infigratinib has promising antitumor activity and a manageable adverse event profile in these patients, representing a new therapeutic option in this setting. In terms of the other approved FGFR inhibitor, pemigatinib, updated results of the FIGHT-202 study supported the primary data that second-line pemigatinib treatment resulted in continued and durable responses and sustained tolerability in patients with CCA harboring FGFR2 rearrangements/fusions. In addition, longitudinal evaluation of quality of life in patients with advanced CCA harboring FGFR fusions/rearrangements treated with pemigatinib showed that patients who achieved responses or stable disease had stable overall health status and emotional functioning.

Several investigational FGFR inhibitors, such as futibatinib, RLY-4008, derazantinib, and gunagratinib, are in varying stages of clinical testing in patients with CCA harboring FGFR2 fusions/rearrangements. Initial results of the FOENIX-CCA2 phase 2 clinical trial of futibatinib in patients with intrahepatic CCA and FGFR2 fusions or other genetic alterations, showed that second-line futibatinib was safe and resulted in durable objective responses in this patient population. Patient-reported outcomes from the FOENIX-CCA2 trial indicated that quality of life and overall health status were maintained among futibatinib-treated patients. Safety and tolerability of futibatinib were further supported by results of a pooled safety analysis, while exposure-safety analysis showed a significant relationship between hyperphosphatemia and futibatinib exposure. RLY-4008, which is designed to selectively target acquired resistance mutations in addition to primary oncogenic FGFR2 alterations, showed favorable tolerability in clinical studies and potential to overcome FGFR inhibitor resistance in patients with advanced CCA. The phase 2 FIDES-01 study demonstrated that derazantinib yielded durable objective responses with a manageable safety profile in this patient population.

Novel therapeutic strategies, including HER2 inhibition, immunotherapy, casein kinase 2, and arginase inhibition, are being evaluated in CCA. MyPathway, the phase 2a multibasket study, demonstrated that dual HER inhibition with pertuzumab plus trastuzumab was well-tolerated in patients with previously treated HER2-positive metastatic biliary tract cancers (BTCs), including CCA. First results of the multicenter phase 2 LEAP-005 trial showed potential efficacy with the combination of lenvatinib and pembrolizumab in advanced solid tumors, including CCA.

Research efforts are also focused on improving chemotherapy options following failure of first-line gemcitabine/cisplatin for patients with advanced BTCs. Results of the NIFTY trial demonstrated that liposomal irinotecan in combination with fluorouracil and leucovorin significantly improved efficacy outcomes compared with fluorouracil and leucovorin in patients with BTC who progressed on gemcitabine/cisplatin, with a manageable adverse event profile. The phase 2 NIFE study will compare the liposomal irinotecan plus 5-fluorouracil/leucovorin regimen to standard-of-care gemcitabine/cisplatin treatment in patients with advanced CCA in the first-line setting.

We are pleased to present the highlights of these topics and more!

Related Items

Phase 1 Results of Gunagratinib in Patients with Advanced Solid Tumors Harboring FGFR Pathway Alterations
2021 Year in Review: Cholangiocarcinoma
A phase 1/2a, first-in-human clinical study demonstrated that the highly selective, irreversible pan-FGFR inhibitor gunagratinib was safe and well-tolerated in patients with advanced solid tumors, including CCA.
Prognostic Value of FGFR2 Alterations in Patients Receiving Systemic Chemotherapy for Intrahepatic CCA
2021 Year in Review: Cholangiocarcinoma
A retrospective analysis indicated the prognostic value of FGFR2 fusions/rearrangements in patients with intrahepatic CCA receiving systemic chemotherapy, which warrants additional study.
FGFR2 Fusion and/or Rearrangement Profiling in Chinese Patients with Intrahepatic CCA
2021 Year in Review: Cholangiocarcinoma
Epidemiologic data assessed the incidence rate of FGFR2 gene fusion or rearrangement in Chinese patients with intrahepatic CCA, including those with heterogeneous FGFR2 partner genes.
A Comprehensive Genomic and Immune Profiling Study of IDH1- and IDH2-Driven Intrahepatic CCA
2021 Year in Review: Cholangiocarcinoma
A comprehensive genomic and immune characterization of IDH-mutated and wild-type intrahepatic CCA revealed significant differences in genetic alterations.
Characteristics of IDH Mutations in Bile Duct Carcinoma in a Chinese Population
2021 Year in Review: Cholangiocarcinoma
A retrospective analysis in a large Chinese patient cohort with bile duct carcinoma indicated that activating IDH1/2 mutations occurred at a lower rate compared with that previously reported in the global population.
Silmitasertib (CX-4945) plus Gemcitabine and Cisplatin as First-Line Treatment for Patients with Locally Advanced or Metastatic CCA
2021 Year in Review: Cholangiocarcinoma
Preliminary evidence suggests that combination treatment with silmitasertib plus gemcitabine/cisplatin as first-line therapy has promising efficacy and a favorable safety profile in patients with locally advanced or metastatic CCA.
Targeted Therapies in CCA: Assessment of US Oncologist Practice Patterns
2021 Year in Review: Cholangiocarcinoma
Findings from a clinical practice assessment identified gaps in knowledge, competence, and confidence regarding testing and the use of targeted therapies in patients with unresectable CCA, underscoring the important role of education in overcoming these gaps.
First-Line Toripalimab plus Lenvatinib in Combination with GemOx Chemotherapy for Advanced Intrahepatic CCA
2021 Year in Review: Cholangiocarcinoma
Results of a phase 2 study indicate that toripalimab and lenvatinib in combination with GemOx chemotherapy provide antitumor activity and reasonable tolerability in patients with advanced intrahepatic CCA.
Comparative Landscape of Actionable Somatic Alterations in Advanced CCA from Circulating Tumor and Tissue-Based DNA Profiling
2021 Year in Review: Cholangiocarcinoma
Findings from a retrospective analysis support the use of both tissue and liquid biopsy biomarker testing to guide therapy selection in patients with advanced CCA, particularly when tissue may not be readily available.
Tibsovo (Ivosidenib) FDA Approved for Advanced or Metastatic Cholangiocarcinoma and IDH1 Mutation
By Loretta Fala
2021 Year in Review: Cholangiocarcinoma
Cholangiocarcinoma (CCA) is an aggressive cancer of the bile duct that forms inside the liver (ie, intrahepatic) or outside the liver (ie, extrahepatic, including perihilar and distal tumors). Individuals with colitis or certain liver diseases may have an increased risk for CCA. Although the precise incidence of CCA is unknown, an estimated 8000 new cases of CCA are diagnosed annually in the United States. It is likely, however, that this number is higher, because CCA is difficult to diagnose and may be misclassified at times.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: